GlassScriptPhysician profile
Maite J Corbin
NPI 1275188559
$2,571.11
in general payments reported to CMS, 2019-2025
28 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $544 · 2023: $605 · 2024: $688 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.83 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $702.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $241.03 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $237.71 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $167.26 | 2021-2025 | |
| Lilly USA, LLC | $156.92 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $144.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.78 | 2022-2024 | Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $90.00 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $86.84 | 2022-2023 | |
| Amgen INC. | $69.54 | 2023-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $59.60 | 2022-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $55.95 | 2024-2025 | Voquezna |
| Alk-Abello, INC | $45.42 | 2025 | Neffy, Odactra, Grastek |
| Astellas Pharma US INC | $39.73 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $39.01 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.56 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.04 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.00 | 2023 | Lyvispah |
| Merck Sharp & Dohme LLC | $32.50 | 2022-2025 | Lagevrio |
| Medtronic, INC. | $30.53 | 2023-2024 | Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Amarin Pharma, INC. | $22.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.85 | 2024 | Xifaxan |
| Dexcom, INC. | $18.30 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $17.28 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.35 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $13.46 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2024 | Zoryve |
| Eisai INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maite Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.